

**Amendments to the Claims**

This listing will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Currently Amended) A pharmaceutical composition for the treatment of osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, and other disorders of bone metabolism, or for accelerating bone growth or repair, which composition is characterized by the inclusion of a peptide (SEQ ID NO: 7)

**pyroGlu-His-Trp-Ser-Xaa<sup>1</sup>-Gly- Xaa<sup>2</sup>- Xaa<sup>3</sup>-Pro-Gly-NH<sub>2</sub> (7)**

**or a salt thereof**

**wherein Xaa<sup>1</sup> is His or Tyr,**

**Xaa<sup>2</sup> is Trp or Leu, and**

**Xaa<sup>3</sup> is Tyr or Arg,**

**provided that when Xaa<sup>1</sup> is Tyr and Xaa<sup>2</sup> is Leu, then Xaa<sup>3</sup> is not Arg.**

2. (Original) The composition according to Claim 1, wherein the composition is used for the treatment of osteoporosis.

3. (Previously Presented) The pharmaceutical composition according to Claim 1, wherein the peptide (SEQ ID NO: 6) is

**pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH<sub>2</sub> (6)**

4. (Original) The composition of Claim 3, wherein the composition is used for the treatment of osteoporosis.

5. (Currently Amended) A method of preparing a pharmaceutical composition for the treatment of osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, or another

disorder of bone growth, which method comprises the mixing of a peptide according to the sequence ~~(SEQ ID NO: 6)~~ (SEQ ID NO: 7)

pyroGlu-His-Trp-Ser-Xaa<sup>1</sup>-Gly- Xaa<sup>2</sup>- Xaa<sup>3</sup>-Pro-Gly-NH<sub>2</sub> (7)

or a salt thereof

wherein Xaa<sup>1</sup> is His or Tyr,

Xaa<sup>2</sup> is Trp or Leu, and

Xaa<sup>3</sup> is Tyr or Arg,

provided that when Xaa<sup>1</sup> is Tyr and Xaa<sup>2</sup> is Leu, then Xaa<sup>3</sup> is not Arg, with one or more pharmaceutically acceptable excipients.

6. (Original) The method of Claim 5, wherein the composition is a treatment of osteoporosis.

7. (Currently Amended) The method of Claim 5, wherein the peptide is (SEQ ID NO: 6) pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH<sub>2</sub> (6).

8. (Currently Amended) A method of treatment of an individual suffering from osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, or another disorder of bone growth, or at risk of so suffering, which comprises the administration to said individual of a therapeutically effective amount of a pharmaceutical composition which includes a peptide according to the sequence (SEQ ID NO: 7)

pyroGlu-His-Trp-Ser-Xaa<sup>1</sup>-Gly- Xaa<sup>2</sup>- Xaa<sup>3</sup>-Pro-Gly-NH<sub>2</sub> (7)

or a salt thereof

wherein Xaa<sup>1</sup> is His or Tyr,

Xaa<sup>2</sup> is Trp or Leu, and

Xaa<sup>3</sup> is Tyr or Arg,

provided that when Xaa<sup>1</sup> is Tyr and Xaa<sup>2</sup> is Leu, then Xaa<sup>3</sup> is not Arg, as an active principal.

9. (Original) The method of Claim 8, wherein the disorder of bone growth is osteoporosis.

10. (Previously Presented) The method of Claim 8, wherein the peptide is (SEQ ID NO: 6)  
pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH<sub>2</sub> (6)

11. (Previously Presented) A new use for a peptide according to the sequence (SEQ ID NO: 7)

pyroGlu-His-Trp-Ser-Xaa<sup>1</sup>-Gly- Xaa<sup>2</sup>- Xaa<sup>3</sup>-Pro-Gly-NH<sub>2</sub> (7)

or a salt thereof

wherein Xaa<sup>1</sup> is His or Tyr,

Xaa<sup>2</sup> is Trp or Leu, and

Xaa<sup>3</sup> is Tyr or Arg,

provided that when Xaa<sup>1</sup> is Tyr and Xaa<sup>2</sup> is Leu, then Xaa<sup>3</sup> is not Arg,

which use is as a therapeutic agent for the treatment of osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, and other disorders of bone growth.

12. (Previously Presented) A new use for a peptide according to the sequence (SEQ ID NO: 6)

pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH<sub>2</sub> (6)

which use is as a therapeutic agent for the treatment of osteoporosis and other disorders of bone growth.